1. Macro Dashboard
| Indicator | Level | 5-Day Δ | Note |
|---|---|---|---|
| KOSPI | 5,730 | +4.8% | 11.8% below MA200 (6,487) · KR Bear |
| KOSDAQ | 724 | –0.4% | 25.6% below MA200 (973) |
| USD/KRW | 1,335 | +1.0% | KRW soft |
| VIX | 18.4 | +0.3% | Stable |
| US 10Y | 5.05% | –8bp | FRED as of Oct 28 · US Bull |
| Brent | $113.5 | –2.0% | WTI $103.4 (Oct 27) |
Regime verdict: Korea Bear — only 17.5% of 2,689 tracked names trade above their 50-day moving average; KOSPI and KOSDAQ are both below MA200. US Bull — NASDAQ (26,185) and S&P 500 (7,720) both hold above their 200-day averages. Data quality: 11/12 macro inputs current; US breadth count methodology partially flagged.
2. Market Wrap
Source: KR Market Snapshot (same-day DB). No same-day full close briefing markdown was available; stale prior-session briefings are excluded.
Thursday’s session exposed a gap between the headline and the market floor. KOSPI’s five-day window shows +4.8%, capturing a strong rally earlier in the week. On October 30 itself, the picture was different: 1,901 names fell against only 470 advancers, the average daily return was –1.74%, and the advance-decline ratio came in at 24.7. That is a risk-off close, not a rally day.
Semiconductor and component names absorbed the most selling. HPSP (403870.KQ, –6.7%), 유진테크 (084370.KQ, –8.0%), LG이노텍 (011070.KS, –6.2%), 삼화콘덴서 (001820.KS, –7.9%), and DB하이텍 (000990.KS, –7.1%) all closed materially lower. What makes this notable is that foreign investors were net buyers into several of these fallen names — a divergence worth monitoring for reversal signals.
Construction continued its recent slide. GS건설 (006360.KS) fell 11.6% with institutions selling. 한화솔루션 (009830.KS) lost 4.2% and 대우건설 (047040.KS) dropped 6.0%.
Bio and pharma bucked the trend. 삼성바이오로직스 (207940.KS) surged 8.9% and drew institutional accumulation. 한미약품 (128940.KS) added 6.8%. 안랩 (053800.KS) rose 18.0% — the sharpest single-stock move on the session — on what appears to be a standalone catalyst, with foreign investors as net buyers.
Institutional and foreign flows diverged sharply. Foreigners sold financials (삼성생명 032830.KS, KB금융 105560.KS) and consumer/auto (에이피알 278470.KS, 현대차 005380.KS, 삼성물산 028260.KS). Institutions countered by accumulating 삼성SDI (006400.KS), 삼성바이오로직스, and 신한지주 (055550.KS) while selling construction.
Derivatives offered mixed signals. Program buy net +4,589억 and ETF creation +21,596억 are positive flow numbers. However, futures basis held negative (–0.33), pointing to a persistent discount on futures relative to spot — a soft risk-appetite signal that qualifies the headline program inflow.
3. Today’s Quality Re-Rating Candidates
Source: KR Meta Screener 2026-10-30. Universe: 91 tickers scored; top 20 ranked; DART overlay checked for 15 names.
The screener intersection summary reported no stocks appearing across two or more standalone screener files today — the PEAD screener was the only independent source included. The Meta Screener fills this gap by aggregating quality fundamentals, smart money flow, cycle re-rating, earnings/PEAD, consensus revision, RS-leadership, and official DART signals into a single ranked list, capping double-counting within the same evidence family. Names with four or more independent evidence families are the priority candidates.
Top 10 Candidates
| Rank | Ticker | Name | Meta Score | Evidence Families | Screeners Hit | Key Metrics |
|---|---|---|---|---|---|---|
| 1 | 425420.KQ | TFE (티에프이) | 54.5 | 4 | QC · SMQ · CR · SME | ROE 16.6%, OP YoY +334%, margin +11.1pp |
| 2 | 080580.KQ | Okins Electronics (오킨스전자) | 48.8 | 4 | QC · CR · PEAD · flow | ROE 15.4%, OP YoY +482%, margin +8.9pp ⚠️ |
| 3 | 086450.KS | Dongguk Pharm (동국제약) | 47.4 | 4 | QC · CR · flow · DART | ROE 9.9%, OP YoY +20%, margin +0.5pp |
| 4 | 072950.KQ | Bitsaem Electronics (빛샘전자) | 46.2 | 2 | QC · CR | ROE 9.6%, OP YoY +77%, margin +1.5pp |
| 5 | 011200.KS | HMM | 43.6 | 5 | SMQ · CU · RS80 · flow · DART | F+QI net +140억, consensus z +0.63 |
| 6 | 068270.KS | Celltrion (셀트리온) | 38.4 | 5 | CR · PEAD · RS80 · flow · DART | OPM 28.1%, margin +14.2pp ⚠️ |
| 7 | 021240.KS | Coway (코웨이) | 36.4 | 4 | QC · RS80 · flow · DART | ROE 17.1%, OP YoY +11% ⚠️ |
| 8 | 003380.KS | Harim Holdings (하림지주) | 34.5 | 3 | CR · RS80 · DART catalyst | Spin-off catalyst filed Oct 26 |
| 9 | 089890.KQ | Coses (코세스) | 26.1 | 3 | CR · CU · DART catalyst | Margin +29.2pp, consensus z +0.57 |
| 10 | 018260.KS | Samsung SDS (삼성에스디에스) | 25.3 | 3 | CR · CU · DART catalyst | 4 official DART catalysts filed |
QC = Quality Compounder · SMQ = Smart Money Quality · CR = Cycle Rerating · SME = Smart Money Earnings · CU = Consensus Up Revision · RS80 = RS80 Not-Late Leadership. ⚠️ = net institutional/foreign selling over the recent 5-day window.
Top 3 in Focus
#1 — TFE (425420.KQ, 티에프이)
TFE is a semiconductor test equipment maker that cleared all four core screener families in a single session — the highest evidence density in today’s candidate list. Operating profit is up 334% year-on-year with a margin expansion of 11.1pp, exactly the kind of earnings leverage the Cycle Rerating screener is designed to capture. Smart money flow confirms the fundamental signal: foreigners and quality institutions absorbed a net 193억 over five days while retail supplied –197억 of stock. A large shareholder disclosure filed via DART on October 23 adds an official event layer. With quality, smart money, cycle, and earnings all independently pointing in the same direction, this is today’s most complete re-rating candidate. The next check is whether the semiconductor equipment cycle has enough quarters of runway to sustain the margin trajectory.
#2 — HMM (011200.KS)
Korea’s largest container shipping group carries five independent evidence families today — Smart Money Quality, Consensus Up Revision, RS80 Not-Late Leadership, official DART events, and price leadership. Foreigners and quality institutions added a net 140억 over the past five days, while consensus estimates moved higher (composite z-score +0.63). A capital expenditure investment disclosure filed October 15 confirms the management team is deploying at scale. HMM sits in the RS80 “Focus Candidate” bucket, meaning it cleared the not-late filter with a pivot gap of +4.4% and a box risk of –14.7%. The primary risk to verify: container spot rates are volatile, and any rate reversal would compress the thesis faster than the consensus models assume.
#3 — Dongguk Pharm (086450.KS, 동국제약)
A domestic pharmaceutical compounder with an ROE of 9.9%, operating profit growth of 20% year-on-year, and two DART filings in October — including an extraordinary general meeting announcement and a record date notice, both filed October 12. Smart money and retail flows confirm net accumulation. The margin expansion of +0.5pp is modest, making this a lower-conviction re-rating signal relative to TFE. The critical check: verify whether the growth is being driven by higher-margin prescription drugs or lower-margin OTC and cosmetics lines, as the earnings quality differs materially between the two.
All data as of 2026-10-30. Macro regime: 11/12 inputs current; US breadth methodology partially flagged. This is market analysis for informational purposes. Screener-flagged candidates require independent due diligence before any investment decision.